{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:21:17Z","timestamp":1790713277879,"version":"4.1.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T00:00:00Z","timestamp":1388620800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2014,1]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Cisplatin\u2010based adjuvant chemotherapy provided a significant advantage in the overall survival (OS<\/jats:styled-content>) of patients with stage II<\/jats:styled-content> and III<\/jats:styled-content> non\u2010small cell lung cancer (NSCLC<\/jats:styled-content>). However, the compliance and toxicity in cisplatin\u2010based treatment were not always satisfactory. Pemetrexed plus carboplatin (PC<\/jats:styled-content>) had better chemotherapy compliance and efficiency in advanced non\u2010squamous NSCLC<\/jats:styled-content> patients. The aim of our study was to investigate the feasibility and efficacy of PC<\/jats:styled-content> as adjuvant chemotherapy in patients with completely resected non\u2010squamous NSCLC<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>Eighty\u2010two eligible non\u2010squamous NSCLC<\/jats:styled-content> patients operated on with pathological stage II<\/jats:styled-content> or IIIA<\/jats:styled-content> were enrolled in this trial. Adjuvant chemotherapy was initiated between one and four weeks after surgery, and consisted of four cycles of pemetrexed (500\u2009mg\/m2) plus carboplatin (AUC<\/jats:styled-content> = 5) every three weeks. The primary endpoint was the compliance of the regimen and the second endpoint was disease\u2010free survival (DFS<\/jats:styled-content>).<\/jats:p><\/jats:sec>Results<\/jats:title>Patient demographics were median age 58 years (range 32 to 78) and gender ratio 68.3% male\/31.7% female. Forty\u2010eight (58.5%) of the patients were at stage II<\/jats:styled-content>, and the other thirty\u2010four (41.5%) patients were at stage IIIA<\/jats:styled-content>. Seventy patients (85.4%) received four cycles of therapy over a 12\u2010week period. Reasons for discontinuing therapy included: patient's refusal (n = 10); severe adverse events (n = 1); and surgical complications (n = 1). The primary grade 3 to 4 adverse reaction was hematologic toxicity: neutropenia (13.4%); leucopenia (7.3%); anemia (3.7%); and thrombocytopenia (2.4%). Non\u2010hematological adverse events were mild. No treatment related deaths were observed. Median DFS<\/jats:styled-content> for stage II<\/jats:styled-content> and IIIA<\/jats:styled-content> patients were 38.0 months (95% confidence interval (CI)<\/jats:styled-content>: 28.1 to 47.9 months) and 21.0 months (95%CI<\/jats:styled-content>: 13.7 to 28.3 months), respectively.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Adjuvant PC<\/jats:styled-content> chemotherapy was an acceptable regimen in resected non\u2010squamous NSCLC<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.12058","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T09:42:42Z","timestamp":1369820562000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non\u2010squamous non\u2010small cell lung cancer"],"prefix":"10.1111","volume":"5","author":[{"given":"Liang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Sun Yat\u2010sen University Cancer Center Guangzhou Guangdong Province China"},{"name":"State Key Laboratory of Oncology in South China Guangzhou Guangdong Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.2.74"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043623"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.01.016"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2004.03.041"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4855"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg059"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70804-X"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031644"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.02.109"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk196"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9114"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31812f3c1a"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(03)00031-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.08.016"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318160c5f1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.5.362"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00795.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.172"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.3.173"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11548"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181fbebfd"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.13.1029"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.5570"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2010.07.005"},{"key":"e_1_2_7_28_1","first-page":"4297","article-title":"Carboplatin\u2010pemetrexed adjuvant chemotherapy in resected non\u2010small cell lung cancer (NSCLC): a phase II study","volume":"29","author":"Karapanagiotou EM","year":"2009","journal-title":"Anticancer Res"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.12058","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.12058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T18:26:14Z","timestamp":1696011974000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.12058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1111\/1759-7714.12058"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.12058","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"2013-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}